372 related articles for article (PubMed ID: 24309019)
21. E. coli Gyrase Fails to Negatively Supercoil Diaminopurine-Substituted DNA.
Fernández-Sierra M; Shao Q; Fountain C; Finzi L; Dunlap D
J Mol Biol; 2015 Jul; 427(13):2305-18. PubMed ID: 25902201
[TBL] [Abstract][Full Text] [Related]
22. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
23. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
24. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
Bau JT; Kang Z; Austin CA; Kurz EU
Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
[TBL] [Abstract][Full Text] [Related]
25. DNA supercoiling and relaxation by ATP-dependent DNA topoisomerases.
Fisher LM; Austin CA; Hopewell R; Margerrison EE; Oram M; Patel S; Plummer K; Sng JH; Sreedharan S
Philos Trans R Soc Lond B Biol Sci; 1992 Apr; 336(1276):83-91. PubMed ID: 1351300
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of DNA topoisomerases I and II by G3 PAMAM-NH2 dendrimer-modified digoxin and proscillaridin A conjugates in a cell free system.
Winnicka K; Bielawska A; Bielawski K
Acta Pol Pharm; 2010; 67(6):630-4. PubMed ID: 21229879
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.
Lok CN; Lang AJ; Mirski SE; Cole SP
Biochem J; 2002 Dec; 368(Pt 3):741-51. PubMed ID: 12197834
[TBL] [Abstract][Full Text] [Related]
29. Examination of the Impact of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα.
Wilson JT; Jiang X; McGill BC; Lisic EC; Deweese JE
Chem Res Toxicol; 2016 Apr; 29(4):649-58. PubMed ID: 26982206
[TBL] [Abstract][Full Text] [Related]
30. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
[TBL] [Abstract][Full Text] [Related]
32. Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.
Bender RP; Osheroff N
Chem Res Toxicol; 2007 Jun; 20(6):975-81. PubMed ID: 17516663
[TBL] [Abstract][Full Text] [Related]
33. HMGB1 interacts with human topoisomerase IIalpha and stimulates its catalytic activity.
Stros M; Bacíková A; Polanská E; Stokrová J; Strauss F
Nucleic Acids Res; 2007; 35(15):5001-13. PubMed ID: 17636313
[TBL] [Abstract][Full Text] [Related]
34. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
35. Single-molecule analysis of DNA uncoiling by a type II topoisomerase.
Strick TR; Croquette V; Bensimon D
Nature; 2000 Apr; 404(6780):901-4. PubMed ID: 10786800
[TBL] [Abstract][Full Text] [Related]
36. Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism.
Lindsey RH; Pendleton M; Ashley RE; Mercer SL; Deweese JE; Osheroff N
Biochemistry; 2014 Oct; 53(41):6595-602. PubMed ID: 25280269
[TBL] [Abstract][Full Text] [Related]
37. Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a-/- mutants.
Sapetto-Rebow B; McLoughlin SC; O'Shea LC; O'Leary O; Willer JR; Alvarez Y; Collery R; O'Sullivan J; Van Eeden F; Hensey C; Kennedy BN
BMC Dev Biol; 2011 Nov; 11():71. PubMed ID: 22111588
[TBL] [Abstract][Full Text] [Related]
38. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
39. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
[TBL] [Abstract][Full Text] [Related]
40. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
